Investing in Lyell Immunopharma Inc. (LYEL) is a safe bet with a significant edge

In the latest session, Lyell Immunopharma Inc. (NASDAQ: LYEL) closed at $4.32 down -1.59% from its previous closing price of $4.39. In other words, the price has decreased by -$0.0700 from its previous closing price. On the day, 933691 shares were traded. LYEL stock price reached its highest trading level at $4.4400 during the session, while it also had its lowest trading level at $4.2525.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



For a deeper understanding of Lyell Immunopharma Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.90 and its Current Ratio is at 12.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on November 14, 2022, Downgraded its rating to Equal-Weight and sets its target price to $7 from $15 previously.

On November 11, 2022, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $13 to $7.

On October 17, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $12.H.C. Wainwright initiated its Buy rating on October 17, 2022, with a $12 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 23 when Klausner Richard sold 11,100 shares for $6.40 per share. The transaction valued at 71,041 led to the insider holds 988,900 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 27.67 while its Price-to-Book (P/B) ratio in mrq is 1.31.

Stock Price History:

Over the past 52 weeks, LYEL has reached a high of $11.06, while it has fallen to a 52-week low of $3.57. The 50-Day Moving Average of the stock is 6.4379, while the 200-Day Moving Average is calculated to be 5.9966.

Shares Statistics:

For the past three months, LYEL has traded an average of 1.11M shares per day and 1.33M over the past ten days. A total of 248.32M shares are outstanding, with a floating share count of 204.22M. Insiders hold about 3.10% of the company’s shares, while institutions hold 63.60% stake in the company. Shares short for LYEL as of Oct 13, 2022 were 19.2M with a Short Ratio of 18.99M, compared to 15.32M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.75% and a Short% of Float of 11.14%.

Earnings Estimates

There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.31 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.39, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.23 and low estimates of -$0.54.

Analysts are recommending an EPS of between -$0.89 and -$1.35 for the fiscal current year, implying an average EPS of -$1.11. EPS for the following year is -$1.56, with 3 analysts recommending between -$0.94 and -$2.

Revenue Estimates

A total of 4 analysts have provided revenue estimates for LYEL’s current fiscal year. The highest revenue estimate was $43.29M, while the lowest revenue estimate was $10.65M, resulting in an average revenue estimate of $32.63M. In the same quarter a year ago, actual revenue was $10.65M, up 206.40% from the average estimate.